Targeted therapies in early-stage breast cancer: Achievements and promises

Surgical Oncology Clinics of North America

Volumn 19, Issue 3, 2010, Pages 669-679

  Sledge, George W ^a   Jotwani, Aparna C ^a   Mina, Lida ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Chemotherapy; HER2; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; BEVACIZUMAB; BSI 201; CALCIUM; CAPECITABINE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GEMCITABINE; LAPATINIB; OLAPARIB; OSTEOCLAST DIFFERENTIATION FACTOR; PACLITAXEL; PLACEBO; PROGESTERONE RECEPTOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VITAMIN D; ZOLEDRONIC ACID; TUMOR PROTEIN;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; DRUG TOLERABILITY; GENE EXPRESSION; GENE MUTATION; HUMAN; MONOTHERAPY; OVARY INSUFFICIENCY; REVIEW; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; DRUG ANTAGONISM; FEMALE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM PROTEINS;

EID: 77954159097     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2010.04.005     Document Type: Review

References (52)

1. Sledge G. What is targeted therapy?. J Clin Oncol 2005, 23:1614-1615.
2. Sorlie T., Perou C., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001, 98:10869-10874.
3. Perou C., Sorlie T., Eisen M., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
4. van de Vijver M., He Y., van't Veer L., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
5. Riese D.J., Stern D.F. Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998, 20(1):41-48.
6. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235(4785):177-182.
7. Hynes N., Stern D. The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1994, 1198:165-184.
8. Ravdin P., Chamness G. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers-a review. Gene 1995, 159:19-27.
9. Slamon D., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
10. Romond E., Perez E., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
11. Piccart-Gebhart M., Proctor M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
12. Slamon D, Eiermann W, Robert N. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study [abstract-A-62]. Presented at the 32nd Annual San Antonio Breast Cancer Symposium. San Antonio (TX), December 9-13, 2009.
13. Pegram M., Finn R., Arzoo K., et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancers cells. Oncogene 1997, 15:537-547.
14. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354(8):809-820.
15. Geyer C., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355(26):2733-2743.
16. Sledge G., Miller K. Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 2002, 26:1-60.
17. Konecny G., Meng Y., Untch M., et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res 2004, 10:1706-1716.
18. Linderholm B., Andersson J., Lindh B., et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur J Cancer 2004, 40:33-42.
19. Hicklin D., Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
20. Ellis L., Hicklin D. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
21. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
22. Miles D., Chan A., Romieu G., et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (AVADO) [abstract LBA 1011]. J Clin Oncol 2008, 26(Suppl 1).
23. Pegram M., Chan D., Dichmann R.A., et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer [abstract 301]. Breast Cancer Res Treat Suppl 2006, 100(Suppl 1).
24. Slamon D., Gomez H., Kabbinavar F., et al. Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2008, 16(155):1016.
25. Schneider B., Wang M., Radovich M., et al. Association of VEGF and VEGFR-2 genetic polymorphisms with outcome in E2100. J Clin Oncol 2008, 26:4672-4678.
26. Schneider B., Sledge G.J. Anti-VEGF therapy as adjuvant therapy: clouds on the horizon?. Breast Cancer Res 2009, 11(3):303.
27. Wirapati P., Sotiriou C., Kunkel S., et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008, 10:R65.
28. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006, 24:3726-3734.
29. Albain K., Barlow W., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11(1):55-65.
30. Schneider B., Winer E., Foulkes W., et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008, 14(24):8010-8018.
31. Comen E., Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer. Oncology (Williston Park) 2010, 24(1):55-62.
32. Martin S., Lord C., Ashworth A. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev 2008, 18(1):80-86.
33. O'Shaughnessy B., Osborne J., Pippen M., et al. Final results of a randomized phase II study demonstrating efficacy and safety of BSI-201, a poly (ADP-Ribose) polymerase (PARP) inhibitor, in combination with gemcitabine/carboplatin (G/C) in metastatic Triple Negative Breast Cancer (TNBC) [abstract 3]. Presented at the San Antonio Breast Cancer Symposium. 2009. J Clin Oncol 2009, 27(Suppl):18s.
34. Tutt A. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. J Clin Oncol 2009, 27:18S.
35. James J., Evans A., Pinder S., et al. Bone metastases from breast carcinoma: histopathological - radiological correlations and prognostic features. Br J Cancer 2003, 89:660-665.
36. Coleman R. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006, 12:6243s.
37. Gralow J., Biermann S., Farooki A., et al. NCCN task force report: bone health in cancer care. J Natl Compr Canc Netw 2009, 7(3):S1.
38. Hillner B., Ingle J., Chlebowski R., et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003, 21:4042-4057.
39. Guise T. Breaking down bone: new insight into the site specific mechanisms of breast cancer osteolysis mediated by metalloproteinases. Genes Dev 2009, 23(18):2117.
40. Hofbauer L., Hosla S., Dunstan C., et al. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000, 15(1):2-12.
41. Harada S., Rodan G. Control of osteoblast function and regulation of bone mass. Nature 2003, 423:349-355.
42. Lacey D., Timms E., Tan H., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998, 93:165-176.
43. Roodman G. Biology of osteoclast activation in cancer. J Clin Oncol 2001, 19:3562-3571.
44. Yasuda H., Shima N., Nakagawa N., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998, 95(7):3597-3602.
45. Roodman G. Mechanisms of bone metastasis. N Engl J Med 2004, 350(16):1655-1670.
46. Jones D.H., Nakashima T., Sanchez O., et al. Regulation of cancer cell migration and bone metastasis by RANKL. Nature 2006, 440:692-696.
47. Bekker P., Holloway D., Rasmussen A., et al. A single-dose placebo-controlled study of AMG1 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004, 19:1059.
48. McClung M., Lewecki E., Cohen S., et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006, 354:821-831.
49. Body J., Facon T., Coleman R., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 2006, 12:1221.
50. Lipton A., Steger G., Figueroa J., et al. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast-cancer related bone metastases. J Clin Oncol 2007, 25:4431-4437.
51. Stopeck A, Body JJ, Fujiwara Y, et al. Denosumab versus zoledronic acid for the treatment of breast cancer patients with bone metastases: results of a randomized phase 3 study [abstract 14LBA]. Presented at the Joint ECCO 15-34th ESMO Multidisciplinary Congress. Berlin (Germany), September 20-24, 2009.
52. Ellis G., Bone H., Chlebowski R., et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008, 26:4875-4882.